Sahajanand Med Tech IPO Explained: CFO Amit Kumar Khandelia On Growth And Outlook

Is Sahajanand Medical Technologies’ ₹475.48 crore IPO worth watching? In this Business Today TV management interview, CFO Amit Kumar Khandelia discusses the company’s business and listing plans. The IPO is entirely an offer for sale, with a price band of ₹327–₹344 per share and a minimum retail investment of ₹14,792. The medtech company develops devices for vascular and structural heart interventions, including stents, balloons and heart valves. Its products were marketed in 77 countries in FY26, and it had 119 granted patents globally as of June 2026. Revenue rose to ₹1,210.5 crore in FY26 from ₹1,024.9 crore in FY25. Watch for insights into its business outlook, financial performance and what investors should assess before making an IPO decision.